FDA Approves Oral Daprodustat to Treat Anemia in Dialysis
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
Study findings support The End-Stage Renal Disease Quality Incentive Program’s composite measure of facility performance, which is revised annually.
Black patients without high-risk APOL1 alleles did not have higher risks for kidney failure.
Furthermore, use of anticoagulants induces higher incidence of GI bleeding in hemodialysis versus peritoneal dialysis patients
GDF-15 adds predictive value to the HAS-BLED score for assessing major bleeding risk.
Current kidney decision aids for patients focus on dialysis and do not address the unique needs of older patients.
The update reflects advances in hepatitis C management, such as antiviral therapy, increased use of hepatitis C kidney grafts, and treatment of glomerular diseases associated with the virus.
Study findings could help inform older patients who opt to start dialysis on what to expect regarding development of their symptom burden, according to investigators.
Under Medicare, patients with kidney failure often must choose between continuing dialysis or enrolling in hospice.
Few facilities report having environmental sustainability strategy in place or undertaking sustainability audits